A Survey of Community Dermatologists Reveals the Unnecessary Impact of Trial-and-Error Behavior on the Psoriasis Biologic Treatment Paradigm

We gratefully thank the physicians who participated in this survey.

Funding

Support for this survey and the journal’s Rapid Service fee was provided by Mindera Corporation.

Medical Writing, Editorial, and Other Assistance

Editorial assistance in the preparation of this article was provided by Evelyn Albu of e4 Health Group. Support for this assistance was funded by Mindera Corporation.

Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures

Bruce Strober is a consultant (honoraria) for AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol Myers Squibb, Connect Biopharma, Dermavant, Equillium, Janssen, Leo, Eli Lilly, Maruho, Meiji Seika Pharma, Mindera, Novartis, Pfizer, GlaxoSmithKline, UCB Pharma, Sun Pharma, Ortho Dermatologics, Regeneron, Sanofi-Genzyme, Ventyxbio, and vTv Therapeutics. He has received speaker honoraria from AbbVie, Eli Lilly, Janssen, and Sanofi-Genzyme. Dr. Strober is the co-Scientific Director of the Cor-Evitas (Corrona) Psoraisis Registry, the Editor-in-Chief (honoraria) of the Journal of Psoriasis and Psoriatic Arthritis, and has received research support from Dermavant, AbbVie, Corrona Psoriasis Registry, Dermira, Cara, and Novartis. David Pariser is a consultant (honoraria) for Atacama Therapeutics, Bickel Biotechnology, Biofrontera AG, Bristol Myers Squibb, Celgene, Dermira, LEO Pharma, Mindera, Novartis, Pfizer, Regeneron, Sanofi, TheraVida, and Valeant. Dr. Pariser has also received research funding from Almirall, Amgen, AOBiome, Asana Biosciences, Bickel Biotechnology, Celgene, Dermavant Sciences, Dermira, Eli Lilly, LEO Pharma, Menlo Therapeutics, Merck, Novartis, Novo Nordisk, Ortho Dermatologics, Pfizer, and Regeneron. Ann Deren-Lewis is an employee of Mindera Corporation. Ms. Deren-Lewis is a Board member of Afecta Pharmaceuticals. She is a consultant (honoraria) for Park Perfection and Ellis Day Skin Science. Tobin Dickerson is an employee and shareholder of Mindera Corporation. Mark Lebwohl is an employee of Mount Sinai and receives research funds from: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Dermavant Sciences, Eli Lilly, Incyte, Janssen Research & Development, LLC, Ortho Dermatologics, Regeneron, and UCB, Inc. Dr. Lebwohl is also a consultant for Aditum Bio, Almirall, AltruBio Inc., AnaptysBio, Arcutis, Inc., Aristea Therapeutics, Arrive Technologies, Avotres Therapeutics, BiomX, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Dr. Reddy’s Laboratories, Evelo Biosciences, Evommune, Inc., Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Helsinn Therapeutics, Hexima Ltd., LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Seanergy, and Verrica. Alan Menter is a consultant (honoraria) for Abbott Labs, Amgen, Boehringer Ingelheim, Eli Lilly, Janssen Biotech, LEO Pharma, Mindera, Novartis, SunPharma, and UCB, Inc. Dr. Menter has also received grant funding from Abbott Labs, Amgen, Boehringer Ingelheim, Celgene, Janssen Biotech, LEO Pharma, Merck, and SunPharma.

Compliance with Ethics Guidelines

This study was determined to be exempt from IRB oversight as per 45 CFR 46.104(d)(2) by the Institutional Review Board (Advarra). All of the participating dermatologists consented to participate in the study electronically. The survey respondents gave consent to participate and were aware that the results of the study would be used for potential publication. Each participant was pre-screened for eligibility and their responses verified. The group was given a unique login and completed the survey electronically. The survey was conducted under a secure link provided by our vendor that was password protected. The study was performed in accordance with the declaration of Helsinki 1964 and its later amendments.

Data Availability

The datasets generated during and/or analyzed during the current study are not publicly available as the data are proprietary to the sponsor of the study.

留言 (0)

沒有登入
gif